April 2021

Contents

Editorial

• HTB: no. 4 – plus HIV and COVID-19 (1 April 2021)

Conference reports

• 28th Conference on Retroviruses on Opportunistic Infections (CROI 2021)

• CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP

• CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF

• CROI 2021: New compounds for prevention and treatment of COVID-19

• Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study

• Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

• Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study

• Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study

• CROI 2021: Presentations from the LEAP workshop 2021

• CROI 2021: Presentations on NATAP.org

Antiretrovirals

• Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir

Guidelines

• BHIVA guidelines on COVID-19 vaccines and people living with HIV: DRAFT online for comment

Other news

• Calls to reverse proposed UK cuts to global health research

COVID-19: HIV and COVID-19 coinfection

• BHIVA advice on access to COVID-19 vaccines and shielding in the UK

COVID-19: vaccine research

• US phase 3 results enable FDA review of the Oxford/AstraZeneca vaccine

PDFs

• HTB: no.4 – plus HIV and COVID-19 (1 April 2021)